Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Director
Project ECHO (Extension for Community Healthcare Outcomes)
Professor of Medicine
University of New Mexico Health Sciences Center
Albuquerque, NM

Topics of Professional Interest:
  • Hepatitis C virus
  • Rural and underserved health care
  • Telehealth
Current Professional Summary:

Dr Arora is the Director of Project ECHO (Extension for Community Healthcare Outcomes). He is a tenured Professor of Medicine in the Department of Internal Medicine at the University of New Mexico Health Sciences Center (UNMHSC). He has been involved in management of viral hepatitis infection for over 15 years, and led the development and implementation of the Hepatitis C Disease Management Program at UNMHSC. Dr Arora developed the Project ECHO model as a platform for service delivery, education, and evaluation. Using video-conferencing technology and case-based learning, primary care providers from rural and underserved areas and prisons are trained and mentored by ECHO’s medical specialists to deliver best-practice management of complex health conditions in their communities or correctional institutions.

Honors and Awards:
  • 21st Century Awards for Best Practices in Distance Learning, United States Distance Learning Association (USDLA) (2010)
  • ASHOKA Fellowship (2009)
  • Leadership in Distance Learning Program Administration Award, United States Distance Learning Association (USDLA) (2009)
  • eHealth Initiative Award, “Transforming Care Delivery at the Point of Care” (2008)
  • Robert Wood Johnson Foundation/Ashoka Foundation Changemakers Competition Winner, “Disruptive Innovations in Health and Healthcare--Solutions People Want” (2007)
Education:
  • Maharajah’s College, Premedical, Jaipur, India (1974)
  • Armed Forces Medical College, MD, Pune, India (1978)
  • Army Hospital, Internship, Delhi, India (1978-1980)
  • Safdurjung Hospital, Residency, Medicine, New Delhi, India (1980-1981)
  • Maimonides Medical Center, Residency, Surgery (1981-1982)
  • Sisters of Charity Hospital, State University of New York at Buffalo, Residency, Medicine (1982-1985)
  • New England Medical Center, Fellowship, Gastroenterology (1985-1987)
Selected Publications:
  1. Arora S, Kalishman S, Dion D, et al. Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. Health Aff (Millwood). 2011;30:1176-1184.
  2. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-2207.
  3. Deming P, Arora S. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011;20:1435-1443.
  4. Arora S, Kalishman S, Thornton K, et al. Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52:1124-1133.
  5. Yu S, Douglass JM, Qualls C, Arora S, Dunkelberg JC. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites. Am J Gastroenterol. 2009;104:1686-1692.
  6. Berkley EM, Leslie KK, Arora S, Qualls C, Dunkelberg JC. Chronic hepatitis C in pregnancy. Obstet Gynecol. 2008;112:304-310.
  7. Arora S, Geppert CM, Kalishman S, et al. Academic health center management of chronic diseases through knowledge networks: Project ECHO. Acad Med. 2007;82:154-160.
  8. Arora S, Thornton K, Jenkusky SM, Parish B, Scaletti JV. Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico. Public Health Rep. 2007;122:74-77.
  9. Geppert CM, Arora S. Widening the door: the evolution of hepatitis C treatment in patients with psychiatric disorders. Hepatology. 2007;46:957-959.
  10. Gish RG, Arora S, Rajender Reddy K, et al. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007;47:51-59.

Presentations

14th Annual Clinical Conference for the Ryan White HIV/AIDS Program